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Controlled delivery of gold nanoparticle-coupled
miRNA therapeutics via an injectable self-healing
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Differential expression of microRNAs (miRNAs) plays a role in many diseases, including cancer and cardio-
vascular diseases. Potentially, miRNAs could be targeted with miRNA-therapeutics. Sustained delivery of
these therapeutics remains challenging. This study couples miR-mimics to PEG-peptide gold nano-
particles (AuNP) and loads these AuNP-miRNAs in an injectable, shear thinning, self-assembling polymer
nanoparticle (PNP) hydrogel drug delivery platform to improve delivery. Spherical AuNPs coated with
fluorescently labelled miR-214 are loaded into an HPMC-PEG-b-PLA PNP hydrogel. Release of AuNP/
miRNAs is quantified, AuNP-miR-214 functionality is shown in vitro in HEK293 cells, and AuNP-miRNAs
are tracked in a 3D bioprinted human model of calcific aortic valve disease (CAVD). Lastly, biodistribution
of PNP-AuNP-miR-67 is assessed after subcutaneous injection in C57BL/6 mice. AuNP-miRNA release
from the PNP hydrogel in vitro demonstrates a linear pattern over 5 days up to 20%. AuNP-miR-214 trans-
fection in HEK293 results in 33% decrease of Luciferase reporter activity. In the CAVD model, AuNP-
miR-214 are tracked into the cytoplasm of human aortic valve interstitial cells. Lastly, 11 days after sub-
cutaneous injection, AuNP-miR-67 predominantly clears via the liver and kidneys, and fluorescence levels
are again comparable to control animals. Thus, the PNP-AuNP-miRNA drug delivery platform provides
linear release of functional miRNAs in vitro and has potential for in vivo applications.
Introduction
Since their discovery, microRNAs (miRNAs) have become a
focus of (bio)medical research. The research community has
elucidated the role of miRNAs in the etiology and progression
of various diseases, including cardiovascular disease,1–3
cancer,4,5 and hepatitis C.6 The discovery of their central role
in several pathological conditions has provided the basis for
using miRNAs in the treatment of these diseases. For example,
miR-34 has been tested in phase I trials to treat multiple types
of cancer (ClinicalTrials.gov: NCT01829971, NCT02862145)
and miR-122 has been explored for the treatment of hepatitis
C.6 The latter successfully completed phase II, whereas the
former two trials were terminated prematurely due to serious
adverse events, including enterocolitis, hypoxia/systemic
inflammatory response syndrome, colitis/pneumonitis, hepatic
failure, and cytokine release syndrome/respiratory failure that
could be attributed to the treatment.7 The mixed outcomes of
these trials highlight the potential of miRNA therapeutics and
the present challenge in their successful delivery to the tar-
geted cells and tissues.
Prior to clinical testing and application, there are several
hurdles for RNA therapeutics to overcome regarding their
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delivery, retention, stability, and degradation. To prevent endo-
somal degradation, miRNAs were functionalized with fuso-
genic pH-sensitive peptides that enabled endosomal escape.8
When miRNAs are injected directly, washout is high and reten-
tion is low.9 Carrier vehicles and modifications have been
explored to reduce the washout and improve the delivery of
miRNAs. We previously described non-viral vectors to improve
delivery, including lipids,10 microbubbles,11 polymers,12 and
inorganic materials,13 as well as modifications to improve both
biostability and binding stability.14 Injectable hydrogels are
promising candidates to improve and localize the delivery of
therapeutic miRNA molecules while allowing minimally inva-
sive application.
Injectable hydrogels have been designed with natural or
synthetic polymers, including ECM,15 collagen, fibrin, algi-
nate, functionalized poly(ethylene glycol) (PEG), or poly(N-iso-
propylacrylamide) (pNIPAM).16 Traditionally, hydrogels have
been based on covalent cross-linking methods that require
initiation by temperature,17 light,18 or a change in pH.19–21 For
biomedical applications, including drug delivery, these
covalent cross-linking methods can provide an additional
hurdle, as the cross-linking reaction is not instantaneous, and
drugs can be lost during network formation. Additionally, for
some materials it requires an external stimulus or an instru-
ment, such as a UV light source. To simplify the application of
hydrogels and avoid the challenges associated with covalent
cross-linking, non-covalent cross-linking allows for spon-
taneous gel formation without an external trigger. In addition,
non-covalent hydrogels often exhibit shear-thinning (the
ability to flow upon application of stress) and self-healing
(reformation of the gel upon relaxation of the external stress)
properties. Shear-thinning facilitates injection and minimally
invasive delivery, thus improving clinical application.
Injectable hydrogels have been developed using leucine
zipper domains,22 dock-and-lock proteins,23 and host–guest
interactions.24 A pH cross-linkable hydrogel was developed for
miRNA delivery based on non-covalent ureido-pyrimidinone
(UPy) cross-linking. Near complete release of miRNA molecules
from UPy gels was achieved after two days.21 This release could
be extended by modification of the miRNA molecules with
cholesterol groups. We recently developed a class of shear-thin-
ning and self-healing hydrogels based on polymer–nano-
particle (PNP) interactions.25,26 These properties arise from the
reversible, non-covalent interactions between the polymer and
the nanoparticles within the gel, employing a hydroxypropyl-
methylcellulose derivative (HPMC-C12) and core–shell nano-
particles [poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-
PLA) nanoparticles].
This research set out to improve both the biostability and
the delivery of miRNA. In order to improve biostability and
reduce degradation, the miRNA molecules were attached to
gold nanospheres (AuNP) that were functionalized with poly
(ethylene-glycol) (PEG).13,27–29 In addition, influenza hemag-
glutinin (HA1) peptide was added to stimulate endosomal
escape intracellularly by destabilizing the endosomal
membrane.
These functionalized AuNP (AuNP-miR) were loaded into a
biocompatible, shear-thinning, and self-healing injectable
hydrogel, based on the PNP gel platform, to improve mini-
mally invasive, local, and sustained delivery. This research
shows (1) linear release of AuNP-miRs from the PNP hydrogel
over multiple days, and (2) that AuNP-miRs retain functionality
in vitro. Additionally, it shows that (3) AuNP-miRs retain func-
tionality by employing an in vitro miRNA reporter assay and a
complex model system, specifically in a 3D in vitro model of
human calcific aortic valve disease.30 Lastly, it shows (4) the
biodistribution of AuNP-miRs after subcutaneous injection
in vivo. Together, this data demonstrates an innovative
approach to achieve controlled release of functional miRNA
from an injectable, self-healing PNP hydrogel.
Results & discussion
Production of AuNP-miR-loaded PNP hydrogels
To engineer an injectable biomaterial for controlled release of
miRNAs, we prepared AuNP-miRNAs within PNP hydrogel for-
mulations. We synthesized the PNP hydrogel components and
functionalized the AuNPs with PEG, cel-miR-67 or has-
miR-214, and HA1-peptide (Fig. S1†). Cel-miR-67 was used as a
negative control as it has minimal sequence identity with
murine or human miRNAs and it is not naturally present in
human cells; thus, it should not have any biological effect. The
HA1 peptide, a fusogenic peptide (influenza hemagglutinin
HA1 peptide, N-YPYDVPDYA-C23) was used to increase miRNA
uptake by destabilizing the endosomal membrane stimulating
endosomal discharge by a pH-responsive machinery.13 This
peptide was functionalized on the surface of the AuNPs via
carbodiimide chemistry assisted by N-hydroxisuccinimide
using an EDC/NHS coupling reaction between the carboxylated
PEG spacer and the amine terminal group of the peptide.
HPMC-C12 and PEG-b-PLA polymers were synthesized as pre-
viously described.25 PEG-b-PLA polymers were formulated into
NPs via nanoprecipitation and characterized by dynamic light
scattering (DLS). PEG-b-PLA NPs with a diameter (Dh) of
∼88 nm and dispersity (Đ) of 0.12 were used to formulate the
PNP hydrogel. Based on prior work, NPs of this diameter form
gels by enabling polymer bridging over several NPs in contrast
to polymer wrapping around single NPs.31 PNP hydrogels were
formulated at 1 wt% HPMC-C12 and 10 wt% PEG-b-PLA NPs
(Fig. 1a).
Linear release of AuNP-miRs from PNP hydrogels
To monitor the release of AuNP-miRs from the PNP hydrogels,
non-modified AuNPs and AuNP-miR-67 were loaded into the
PNP hydrogel in a 1 : 1 : 1 ratio (PEG-b-PLA : HPMC-C12 : AuNP;
final concentration AuNP-miR-67 0.34 nM) and incubated at
37 °C, 5% CO2. The supernatant was collected and replaced at
24 h intervals to quantify the concentration of AuNPs in the
supernatant based on a calibrated absorbance measurement
(Fig. S2†). Sustained linear release of AuNP-miR-67 was
observed up to ∼20% of the loaded AuNPs over the course of 5
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days (Fig. 1b), demonstrating extended release compared to
other hydrogel-based drug-delivery systems.14,20,31–33,35
Following an initial burst release of ∼10% of the loaded AuNP
over the first 24 h, ∼3% of the loaded AuNP were released per
day over the course of 5 days. The observed linear release was
consistent with an erosion-based release that has been
observed for NP release from PNP hydrogels.25
AuNP-miR-214 demonstrates in vitro mRNA targeting activity
Next, we verified the mRNA targeting capacity of miR-214 after
conjugation to the AuNPs. HEK293 cells were transfected with
a miR-214 target luciferase reporter34 and incubated with
AuNP-miR-214s. Compared to a non-transfected control and
an inactive AuNP-miR-67 control, AuNP-miR-214 significantly
reduced the Luciferase signal (∼42%) after 48 h, demonstrat-
ing preserved miR-214 bioactivity after coupling to the AuNP
(Fig. 2). As a positive control, transfection with unmodified
miR-214 mimics using Lipofectamine resulted in a knockdown
of ∼67% relative to the control groups. The higher transfection
efficiency of Lipofectamine compared to AuNP-miR-214 is
expected, considering the thorough optimization of commer-
cially available Lipofectamine.
Suppression of a target gene up to 90% has been observed
for small interfering RNA (siRNA) released from alginate or
collagen hydrogels in a green fluorescent protein (GFP) expres-
sing HEK293 cell line,33 though over a longer time scale of 6
days. 80% knockdown of GFP signal was achieved with miRNA
released from a PEG hydrogel over a period of 42 days.36 This
suggests that an extended testing period for AuNP-miR-214
should be considered for translational use.
AuNP-miR-67 infiltrate haVICs in a 3D bioprinted in vitro
CAVD model
In order to test AuNP-miR uptake in a more complex tissue
model, we tracked fluorescently labelled AuNP-miR-67 in a 3D
model of CAVD. Cel-miR-67 was used as a negative control as it
has minimal sequence identity with murine or human
miRNAs and it is not naturally present in human cells; thus, it
Fig. 1 (A) schematically represents the structure of the PNP hydrogel and the functionalized AuNP-miRs. (B) Depicts in vitro release profile of
AuNP-miRs from the PNP hydrogel at 37 °C demonstrating the cumulative sustained release of AuNP-miRs in a linear pattern of up to ∼20% [Mt/M∞;
the cumulative fractional mass released at time t (n = 3)]. R2 = 0.9875, Mt/M∞ = 0.0012 t + 0.0688.
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should not have any biological effect. Cy5.5-labelled AuNP-
miR-67 were added to the cell culture media of a 3D bioprinted
model of CAVD containing human aortic valve interstitial cells
(haVICs).30 In this model, VICs cultured in NM maintain a
quiescent phenotype and VICs exposed to OM produce micro-
calcifications (Fig. S3†). Labeling nuclei with Hoechst (blue),
cytoplasm with CellTracker Green (green), and lysosomes with
LysoTracker Red (red) aided in demonstrating that AuNP-
miR-67 (white) were taken up by the cells in lysosomes
(Fig. 3a), indicated by co-localization (pink arrows) of
CellTracker Red and the Cy5.5-labelled AuNP-miR-67 (Fig. 3b).
We hypothesize that AuNP-miRs are taken up via endocytosis,
indicated by co-localization (pink arrows) of CellTracker Red
and white AuNP-miR-67, and that they can escape the lyso-
somes, indicated by the presence of both lysosomes (red
arrows) and AuNP-miRs (white arrows).
AuNP-miR-214 increase alkaline phosphatase expression in a
3D CAVD model
Additionally, we employed the 3D bioprinted in vitro human
CAVD model to test AuNP-miR-214 functionality.30 Osteogenic
medium (OM) has been shown to stimulate the formation of
calcium minerals through osteogenic differentiation of
haVICs.30 miR-214 was found to increase calcification of
haVICs in vitro in traditional 2D cell culture.37 Here, we
demonstrate that compared to non-transfected controls 30 nM
AuNP-miR-214 transfection significantly increased ALP activity,
a phospholytic enzyme associated with early calcification in
CAVD,38 in haVICs within a 3D-bioprinted in vitro model of
human CAVD cultured in normal medium (NM) (Fig. 4).
Compared to NM, OM increased ALP activity (left column),
confirming earlier results.39 Compared to NM, addition of
AuNP-miR-214 significantly increased ALP activity (Fig. 4a top
row; Fig. 4b). The difference between the effect of AuNP-
miR-214 and OM on haVICs was likely due to the relatively low
concentration of AuNP-miR-214 and the prolonged exposure to
OM. These findings further support a role for miR-214 in the
development of CAVD by stimulating ALP and encourage
further investigation.
The involvement of miR-214 in CAVD is a relatively recent
discovery, and its precise role in CAVD requires further clarifi-
cation. miR-214 involvement in CAVD was first identified in
porcine AV endothelial cells (paVECs).40 Specifically, micro-
array analysis and ex vivo validation of healthy ventricular and
aortic paVECs RNA yielded differential expression levels of
miR-214 as a result of oscillatory shear due to disturbed blood
flow. Compared to the ventricularis side, increased expression
of miR-214 in the fibrosa side of pAVs resulted in thickening
and calcification. Later, in a comparison between valves of
healthy controls and patients with calcific aortic stenosis,
miR-214 was increased in CAVD patients and osteocalcin,
osteopontin, Runx2, and osterix were identified and validated
as its targets.41 Furthermore, in excised AVs from patients with
CAVD, increased miR-214 expression was found to play a role
in suppressing the apoptosis repressor with caspase recruit-
ment domain ARC.42 In addition, it was demonstrated that
miR-214 stimulates the formation of calcific nodules in
haVICs in vitro via the MyD88/NF-κB inflammatory pathway.37
Contradictory to the aforementioned results, in larger micro-
array studies miR-214 was found low in valves from patients
with CAVD compared to non-diseased control valves.43–45
Furthermore, dynamic stretch on porcine AVs ex vivo demon-
strated that miR-214 was significantly downregulated during
late stage calcification, and addition of miR-214 mimic in
static stretch conditions resulted in lower levels of calcifica-
tion. Therefore, the role of miR-214 in the development of
CAVD is complex and needs to be further elucidated.46
AuNP biodistribution following subcutaneous implantation in
PNP hydrogels
We further investigated the biodistribution of AuNP-miRs fol-
lowing delivery from the PNP hydrogel in vivo. In general, par-
enteral administration of therapeutics or drug delivery systems
via injection can be achieved easily and in a minimally inva-
sive manner. However, traditional intravenous injections result
in relatively short residence time in the body. On the other
hand, surgical implantation of a material-based controlled
release system provides longer-lasting effects but is more inva-
sive. Injectable hydrogels with controlled release provide an
attractive method to administer drugs locally, in a minimally
invasive manner, and with extended biological effect. For
example, hyaluronic acid-based PNP hydrogels were recently
Fig. 2 AuNP-miR-214 significantly reduces Luciferase activity. AuNP-
miR-214 were added to HEK293 cells introduced to the
pMIR-REPORT-QKI-3’ UTR Luciferase vector in vitro. Compared to an
untransfected control and an inactive control AuNP-miR-67, AuNP-
miR-214 suppresses the Luciferase signal (∼42%) after 48 h. Transfection
with miR-214 mimic using Lipofectamine results in knockdown of ∼67%
relative to the control groups, compared to ∼42% in the AuNP-miR-214
transfection. Mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001; n = 6,
experiment conducted in triplicate.
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administered to cardiac tissue via catheter-based delivery.47
Therefore, we employed AuNP-miR-loaded PNP hydrogels for
administration of an AuNP-miR releasing depot following
minimally invasive subcutaneous injection. AuNP-miR-67-
loaded PNP hydrogel was injected subcutaneously in nine
C57BL/6 mice to assess biodistribution. Cel-miR-67 was used
as a negative control as it has minimal sequence identity with
murine or human miRNAs and it is not naturally present in
human cells; thus, it should not have any biological effect. To
monitor the biodistribution of the AuNP-miR, fluorescent
signals of the Cy5.5 labelled miR-67 were measured in the
lungs, liver, spleen, kidney, and skin surrounding the injection
site in three adult male wildtype C57BL/6 mice on days 1, 4,
and 11 after injection (Fig. 5). Three additional animals were
injected with unloaded PNP hydrogel as negative control and
aforementioned tissues were harvested and monitored on day
11. Image quantification of the fluorescent signal of the
labelled AuNP-miR-67 demonstrated accumulation in the
lungs, spleen, liver and kidney on day 1 and suggests clearance
via the liver and kidney by day 11, as demonstrated by decreas-
ing fluorescence that approached the values of control animals.
Experimental section
PNP hydrogel synthesis
PNP hydrogels were synthesized as previously described.25 In
short:
HPMC-C12 synthesis. Briefly, hydroxypropylmethylcellulose
(HPMC; Sigma h7509-100G; 1.0 g) was dissolved in
Fig. 3 Infiltration of AuNP-miR-67 into human aortic valve interstitial cells (haVICs) in a 3D bioprinted model of calcific aortic valve disease (CAVD).
Nuclei were labelled with Hoechst (blue), haVICs were labelled with CellTracker Green (green), and lysosomes were labelled with LysoTracker Red
(red). Co-localization of lysosomes (red) and Cy5.5-labelled AuNP-miR-67 (white) demonstrated that AuNP-miRs were taken up by the cells in lyso-
somes (scale bar = 20 µm, scale bar insert = 5 µm, t = 48 h, n = 3).
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Fig. 4 AuNP-miR-214 increase alkaline phosphatase expression (red) after 48 h in human aortic valve interstitial cells (haVICs) comparable to osteo-
genic stimulation in 3D human calcific aortic valve disease model. Brightfield microscopy, mean ± SEM, *** p < 0.001, n = 3, 20× magnification.
Fig. 5 To assess biodistribution of AuNP-miR-67 n = 9 C57BL/6 mice were injected subcutaneously with PNP-AuNP-miR-67. (Top) Fluorescent
signals of the Cy5.5 labelled AuNP-miR-67 were measured in the lungs, liver, spleen, kidney, and skin surrounding the injection site in n = 3 animals
on days 1, 4, and 11 after injection. N = 3 mice were injected with unloaded PNP hydrogel as a control and aforementioned tissues were harvested
on day 11. Intensity of the fluorescent signal of labelled AuNP-miR-67 demonstrates accumulation in the lungs, spleen, liver and kidney on day 1
and clearance via the kidneys after 11 days, as demonstrated by decreasing fluorescent signal comparable to control animals. (Bottom) Quantified
fluorescent signal in liver, kidney, lung, spleen, and skin surrounding the injection site on days 1, 4, and 11 demonstrates clearance over 11 days.
N = 3 animals per time point. Mean ± SEM.
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N-methylpyrrolidone (NMP; 45 mL) by magnetic stirring at
80 °C for 1 h. After cooling the solution to room temperature,
a solution of 1-dodecylisocyanate (Sigma 389064-5G;
0.5 mmol) and triethylamine (2 drops) were dissolved in
N-methylpyrrolidone (Sigma PHR1352-2G; 5 mL) and added to
the reaction mixture. The mixture was stirred at room tempera-
ture for 16 h. This solution was then precipitated from acetone
and filtered to recover the polymer, which was dried under
vacuum at room temperature for 24 h and weighed, yielding
the functionalized HPMC-C12 as a white amorphous powder
(0.96 g, 87%).
PEG-block-PLA synthesis. PEG (Sigma 373001-250G; 0.25 g,
4.1 mmol) and 1,8-diazabicyloundec-7-ene (DBU; Sigma
139009-25G; 10.6 mg, 10 mL, 1.0 mol% relative to LA) were dis-
solved in dichloromethane (DCM; 1.0 mL). LA (Sigma 767344-
5G; 1.0 g, 6.9 mmol) was dissolved in DCM (3.0 mL) with mild
heating. The LA solution was then added rapidly to the PEG/
DBU solution and stirred rapidly for 10 min. Acetone (7.0 mL)
addition then quenched the reaction and the PEG-b-PLA copo-
lymer was precipitated from cold diethyl ether, filtered for col-
lection, and lyophilized to yield a white amorphous polymer
(1.15 g, 92%). GPC (THF): Mn (Đ): 25 kDa (1.09).
PEG-block-PLA NP preparation. A solution of PEG-b-PLA in
DMSO (40 mg mL−1) was added dropwise to water (10 v/v)
under a high stir rate. NPs were purified by ultracentrifugation
over a filter (molecular weight cut-off of 10 kDa; Millipore
Amicon Ultra-15) and resuspended in water to a final concen-
tration of 150 mg mL−1. NP size and dispersity were character-
ized by DLS.
PNP hydrogel preparation. PNP gels were prepared by first
dissolving the HPMC-C12 polymer in water (3 wt%, 30 mg
mL−1) with stirring and mild heating. NPs were concentrated
to 15 wt% solutions. HPMC-C12 polymer solution (100 mg)
and NP solution (200 mL) were then combined and mixed well
by alternately vortex and centrifugation (to remove air bubbles
arising from mixing).
AuNP-miR synthesis
AuNP-miRs were synthesized as previously described.13 In
summary:
Functionalization of AuNP with PEG. Briefly, bare AuNP
(20 nm gold nanospheres from Cytodiagnostics Inc.
G-20–1000; 10 nM) dispersed in aqueous solution of 18 MEG
DI Water were mixed with a commercial hetero-functional PEG
(α-Mercapto-ω-carboxy PEG solution, HS-C2H4-CONH-PEG-O-
C3H6-COOH, MW. 3.5 kDa, Sigma 712515-100MG; 0.006 mg
mL−1) in an aqueous solution of SDS (0.08%). Centrifugation
(20 000g, 30 min, 4 °C) removed excess PEG, which was quanti-
fied by the Ellman’s Assay. The excess of thiolated chains in
the supernatant was quantified by interpolating a calibration
curve set by reacting α-Mercapto-ω-carboxy PEG solution
(200 μL) in phosphate buffer (100 μL, 0.5 M, pH 7) with 5,5′-
dithio-bis(2-nitrobenzoic) acid (DTNB, 7 μL, 5 mg mL−1) in
phosphate buffer (0.5 M, pH 7) and measuring the absorbance
at 412 nm after 10 min reaction. The linear range for the PEG
chain obtained by this method is 0–0.1 mg mL−1 (Abs at
412 nm = 8.0353 × [PEG, mg mL−1] + 0.0486). The number of
exchanged chains is given by the difference between the
amount determined by this assay and the initial amount incu-
bated with the AuNP. There is a point at which the AuNP
becomes saturated with a thiolated layer and is not able to
take up more thiolated chains – maximum coverage per AuNP,
which was 0.03 mg mL−1 of PEG for these AuNP. The AuNP
were functionalized with 50% PEG layer in order to leave space
for binding the thiolated miRNAs and HA1 peptide (Fig. S1†).
Functionalization of AuNP with miRNA molecules. AuNP
were functionalised with Cy5.5-labelled miRNA against hsa-
miR-214-3p (ACAGCAGGCACAGACAGGCAGU) or cel-miR-67-5p
(CGCUCAUUCUGCCGGUUGUUAUG). Briefly, thiolated miRNA
(Thermo Scientific Dharmacon) was dissolved in DTT (1 mL,
0.1 M), extracted three times with ethyl acetate, and further
purified through a desalting NAP-5 column (Pharmacia
Biotech) according to the manufacturer’s instructions. The
miRNA was only resuspended in DEPC-water and incubated
immediately with AuNP previously functionalized with PEG.
The purified thiolated miRNAs (10 μм) were incubated with
RNase-free solution of the PEG-AuNP (10 nM) containing
0.08% SDS. Subsequently, the salt concentration was increased
from 0.05 to 0.3 M NaCl with brief ultrasonication following
each addition to increase the coverage of oligonucleotides on
the AuNP surface. After functionalization at 4 °C for 16 h, the
particles were purified by centrifugation (20 000g, 20 min,
4 °C), and re-suspended in DEPC-water. This procedure was
repeated 3 times. The number of miRNA per AuNP was deter-
mined by quantification of the excess miRNA oligos in the
supernatants collected during synthesis via the emission
spectra of Cy5.5 (excitation/emission, 688 nm/707 nm) dye in a
microplate reader (Varioskan Flash Multimode Reader;
Thermo Scientific). All nanoparticle samples and standard
solutions of the thiolated-miRNAs were kept at the same pH
and ionic strength for all measurements. Fluorescence emis-
sion was converted to molar concentrations by interpolation
from a standard linear calibration curve prepared with known
concentrations of miRNA (Fig. S4†).
HA1 peptide functionalization. The HA1 (N-YPYDVPDYA-C)
peptide was coupled to the functionalized AuNP using carbodi-
imide chemistry assisted by N-hydroxisuccinimide using
an EDC/NHS coupling reaction between the carboxylated
PEG spacer and the amine terminal group of the peptide.
HA1 peptide, which is used to enhance the miRNA uptake,
was functionalized on the AuNP after miRNA function-
alization. Briefly, 10 nM of NPs-PEG, 1.98 mg mL−1
N-hydroxysulfosuccinimide (sulfo-NHS, Sigma) and 500 μg
mL−1 EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide,
Sigma) were incubated in 10 mM MES (2-(N-morpholino)etha-
nesulfonic acid, Sigma) at pH 6.2 and allowed to react for
30 min to activate the carboxylic groups. After this, activated
AuNP were washed once with 10 mM MES, pH 6.2 and used
immediately. HA1 was added to the mixture (final concen-
tration 3 μg mL−1) and allowed to react for 16 h at 25 °C. After
this period, the AuNP were centrifuged at 20 000g for 30 min at
4 °C and washed three times with Milli-Q water.
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HA1 quantification was performed with the Pierce® BCA
Protein Assay kit (Thermo Scientific) according to manufac-
turer’ instructions. Briefly, each standard (0.025 mL) and
unknown sample (the supernatants; 0.025 mL) was mixed with
the BCA™ Working Reagent (50 : 1, BCA reagent A : BCA
reagent B; 0.2 mL) to each tube. The reaction mixture was incu-
bated at 60 °C for 30 min. After incubation, the tubes were
cooled down to room temperature and the absorbance
measured at 562 nm. The standard curve was used to deter-
mine the HA1 concentration of each unknown sample (super-
natant). The calibration curve for a working range (0–125 μg
mL−1) is given by the following equation Abs 562 nm = 0.0036
× [HA1 peptide, μg mL−1] + 0.8016, R2 = 0.9939 for HA1
peptide (Fig. S4†).
Release of AuNP-miRs from PNP hydrogel
AuNP-miR-214 were loaded into PNP hydrogels and incubated
at 37 °C, 5% CO2 with MilliQ water in 1.5 mL Eppendorf tubes.
Supernatant was collected at regular 24 h intervals and the
absorbance of the supernatant was measured at 524 nm on a
Tecan Infinite 200 (Tecan Group Ltd. Männedorf, Switzerland)
plate reader from 400 nm to 700 nm. The calibration curve
based on a standard series of AuNP and AuNP-miRs (0.0–1.0
nM) is given by the following equations: Abs 524 nm = 0.299 ×
[AuNP] + 0.0044, R2 = 0.9984, and Abs 524 nm = 1.4239 ×
[AuNP-miRs] – 0.0048, R2 = 0.9986, respectively.
HEK293 cell culture
Human embryonic kidney 293 (HEK293) cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM; ThermoFisher
Gibco, supplemented with 10% FBS (ThemoFischer Gibco),
1% Pen/Strep (ThermoFisher Gibco 15070063), 1% Non-
Essential Amino Acids NEAA (ThermoFisher Gibco11140050),
1% Sodium Pyruvate (ThermoFisher Gibco, 11360070), on 2%
gelatin coated until confluent. For experiments, cells were
seeded at 25 000 cells per well in media (100 μL) in a 96 well
plate.
Luciferase/beta-galactosidase cell transfection and reporter
assay. Cells were transfected at 60–70% confluence with
Luciferase and beta-Galactose (β-Gal) pMIR-REPORT vectors as
previously described.34 Briefly, the conserved miR-214-binding
sequences in the Quaking (QKI) 3′ untranslated region (UTR)
were cloned into the pMIR-REPORT Luciferase vector
(Ambion).
To assess the suppression efficiency of AuNP-miR-214,
HEK293 cells were co-transfected with pMIR-REPORT-QKI-3′
UTR Luciferase vector (100 ng) and a pMIR-REPORT β-Gal
control plasmid (100 ng) in OptiMEM for 4 h to evaluate trans-
fection efficiency. Subsequently, pre-miR-214 (60 nM) was deli-
vered using Lipofectamine 3000 (ThermoFisher, L3000015).
AuNP-miR-214 and AuNP-miR-67, as a scramble control
microRNA, were added directly to the OptiMEM. Luciferase
and β-Gal activity was assessed after 48 h with the Steady-Glo
Luciferase Assay Kit (Promega E2520) and β-Gal assay buffer
(200 mM sodium phosphate, 2 mM magnesium chloride,
100 mM beta-mercaptoethanol, 1.33 mg mL−1 ortho-nitrophe-
nyl-β-galactoside (ONPG) in water), respectively. Luciferase
activity was assessed by measuring luminescence and β-Gal
activity was determined by measuring absorbance at 405 nm
and 570 nm. Six biological replicates were transfected per con-
ditions. Experiments were conducted in triplicate.
3D Calcific aortic valve disease (CAVD) model
A 3D in vitro model of human CAVD was employed to image
AuNP-miRs uptake into cells. We previously published a
detailed description and validation of this model.30 Briefly,
human aortic valves were obtained from patients undergoing
valve replacement surgery at Brigham and Women’s Hospital
(Boston, MA, USA) as a result of aortic valve (AV) calcific steno-
sis. Leaflets were obtained and utilized in accordance with pro-
tocols approved by the Institutional Review Board (IRB proto-
col #2011P001703/PHS). Valvular interstitial cells (VICs) were
isolated as previously described.48 In short, CAVD AV leaflets
were cut into 5 mm × 5 mm pieces, incubated in collagenase
(Roche 10103586001; 10 mL) solution at 37 °C, 5% CO2 for
12 h, and homogenized with a serological pipette. The
digested tissue was centrifuged, the supernatant aspirated,
and the pellet resuspended in VIC cell culture media [DMEM
supplemented with 10% FBS (ThermoFisher, Gibco) and 1%
P/S (ThermoFisher, Gibco); 5 mL]. The cells were then centri-
fuged a second time, resuspended in VIC cell culture media
(10 mL), and plated in a T75 culture flask. Media was replen-
ished every 48 h. VICs of passage five were used for further
experiments. VICs were incorporated in hydrogel pre-polymers
by mixing VICs and media (to a final concentration of 10 × 106
cells per mL in the gel) with a GelMA (10 wt%), HAMA
(3 wt%), and LAP solution (5 wt%) at 37 °C to form a GelMA
(5%), HAMA (1%), and LAP (0.3%) hydrogel. GelMA and
HAMA were synthesized as previously described.49,50
Constructs were designed in Tinkercad (AutoDesk, Inc., San
Rafael, CA, USA), and encoded using Repetier-Host (version
2.0.0; Hot-World GmbH & Co. KG, Willich, Germany), and
Sublime Text 3 (Sublime HQ, Pty Ltd., Darlinghurst, NSW,
Australia). 3D bioprinting was performed using the Inkredible
+ (Cellink, Cambridge, MA, USA). Pluronic gel (Pluronic F-127;
Allevi, Philadelphia, PA, USA) was printed as a cylindrical mold
(outer diameter = 9.0 mm, inner diameter = 8.6 mm, height =
1.5 mm) using a stainless steel needle nozzle (JG27-0.25HPX;
Jensen Global Inc., Santa Barbara, CA, USA) at a fill density of
95%, layer height of 0.1 mm, printing speed of 4 mm s−1, and
printing pressure of 320 kPa. The second extruder was filled
with the required hydrogel pre-polymer compositions and
heated to 37 °C. A hydrogel disc was then printed inside the
mold from the second extruder using a 23 g stainless steel
nozzle (Fisnar 5901005, Ellsworth Adhesives, Germantown,
WI, USA) by opening the valve of the second extruder for
40 ms at 15–20 kPa. Cross-linking the pre-polymers for 90 s
with 365 nm UV light produced 8.6 mm × 1.0 mm hydrogel
discs. The UV light was calibrated to an intensity of 2.5 mW
cm−2 using a radiometer (85009, Sper Scientific Direct,
Scottsdale, AZ, USA). After printing, the Pluronic gel was dis-
solved by washing in cold PBS. One day after printing, hydro-
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gels were switched to normal media (NM; 10% FBS, 1% P/S) or
osteogenic media (NM supplemented with 10 nM dexametha-
sone, 10 ng mL−1 ascorbic acid, and 10 mM
β-glycerolphosphate) as previously described,51 for up to 14
days. Media was changed every 48 h for all constructs. Cells
were transfected with miR-214 (30 nM) by addition of AuNP-
miR-214 to the cell culture media 48 h prior to imaging.
CellTracker/LysoTracker and confocal imaging
To trace the AuNP-miRs into the cells in the 3D CAVD model
LysoTracker Red (ThermoFisher, L7528; 50 nM), CellTracker
Green (ThermoFisher, C2925; 10 mM) dyes, and Hoechst
33342 (ThermoFisher, H1399) were added according to the
manufacturer’s protocol. CellTracker Green was incubated
overnight at 37 °C, 5% CO2, LysoTracker Red was incubated for
1 h at 37 °C, 5% CO2, Hoechst (1 : 5000) was added and incu-
bated for 30 min at 37 °C, 5% CO2, prior to imaging. Z-stack
images of the constructs were taken on a ZEISS LSM 880
Confocal Microscope with AiryScan.
Animal procedures
All animal procedures were performed according to MIT Animal
Care and Use Committee approved protocols. Adult male
C57BL/6 mice were injected subcutaneously on the back with
PNP-AuNP-miR-67 gels (100 μL; HPMC-C12 1 wt%; PEG-b-PLA
NPs 10 wt%; AuNP-miR-67 85 nM) using a 26G syringe. At 1, 4,
and 11 days following injection 3 animals per time point were
sacrificed and lung, spleen, liver, kidneys and the tissue sur-
rounding the injection site were harvested, flash-frozen, and
stored until further analysis. Fluorescence reflectance of tissues
was measured using a Kodak Image Station 4000 mm Pro.
Statistics
Quantitative data is given as mean ± standard error. The
number of independent experiments is given as n. Statistical
analyses were performed with GraphPad Prism 7 (GraphPad
Software, La Jolla, CA, USA), Student’s t-tests were performed
for two-group comparisons, and for multiple group compari-
sons one-way or two-way ANOVA with Tukey’s post-hoc HSD
tests were used as appropriate. P-Values < 0.05 were considered
statistically significant.
Conclusion
In conclusion, our data demonstrate that AuNP-miRs can be
delivered via a minimally invasive, injectable self-assembling
hydrogel, expressing controlled release. We showed that
approximately 20% of AuNP-miRs were released from the PNP
hydrogel over 5 days. Additionally, we observed that AuNP-
miR-214 remained functional after delivery in both a 2D
in vitro miR-214 target luciferase reporter assay and in a 3D
bioprinted human CAVD model. Furthermore, we demon-
strated that AuNP-miRs were cleared after 11 days in mice fol-
lowing subcutaneous injection of the PNP-AuNP-miR hydrogel
delivery system. Without any cell-targeting ligands, these sub-
cutaneously administered AuNP-miRs were taken up by the
spleen, lungs, and liver, and were disposed via renal excretion.
Additional targeting ligands and site- specific delivery could
tailor this platform to specific cells or tissues, especially in
combination with RNAi molecules adapted to a specific tissue,
cell type, or disease.
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